BR9809457A - Sais de peptìdeo de bpc com atividade organo-protetora, o processo para sua preparação e seu uso em terapia. - Google Patents

Sais de peptìdeo de bpc com atividade organo-protetora, o processo para sua preparação e seu uso em terapia.

Info

Publication number
BR9809457A
BR9809457A BR9809457-2A BR9809457A BR9809457A BR 9809457 A BR9809457 A BR 9809457A BR 9809457 A BR9809457 A BR 9809457A BR 9809457 A BR9809457 A BR 9809457A
Authority
BR
Brazil
Prior art keywords
therapy
preparation
protective activity
organo
peptide salts
Prior art date
Application number
BR9809457-2A
Other languages
English (en)
Other versions
BR9809457B1 (pt
Inventor
Predrag Sikiric
Marijan Petek
Sven Seiwerth
Branko Turkovic
Zeljko Grabarevic
Ivo Rotkvic
Stjepan Mise
Marko Duvnjak
Ivan Udovicic
Original Assignee
Predag Sikiric
Peter Marijan
Sven Seiwerth
Branko Turkovic
Zeljko Grabarevic
Ivo Rotkvic
Stjepan Mise
Marko Duvnkak
Ivan Udovicic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Predag Sikiric, Peter Marijan, Sven Seiwerth, Branko Turkovic, Zeljko Grabarevic, Ivo Rotkvic, Stjepan Mise, Marko Duvnkak, Ivan Udovicic filed Critical Predag Sikiric
Publication of BR9809457A publication Critical patent/BR9809457A/pt
Publication of BR9809457B1 publication Critical patent/BR9809457B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Patente de Invenção: <B>"SAIS DE PEPTìDEO DE BPC COM ATIVIDADE ORGANO-PROTETORA, O PROCESSO PARA SUA PREPARAçãO E SEU USO EM TERAPIA"<D>. A presente invenção descreve novas composições farmacêuticas úteis para o tratamento de várias doenças de ser humano ou de animal. As composições farmacêuticas contêm um ou mais peptídeos.
BRPI9809457-2A 1997-05-23 1998-05-20 sal de peptìdeo de bpc com atividade organo-protetora, composição farmacêutica ou diagnóstica, usos e processos de preparação. BR9809457B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97108384.5 1997-05-23
EP97108384 1997-05-23
PCT/EP1998/002953 WO1998052973A1 (en) 1997-05-23 1998-05-20 New bpc peptide salts with organo-protective activity, the process for their preparation and their use in therapy

Publications (2)

Publication Number Publication Date
BR9809457A true BR9809457A (pt) 2000-06-20
BR9809457B1 BR9809457B1 (pt) 2010-11-30

Family

ID=8226822

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9809457-2A BR9809457B1 (pt) 1997-05-23 1998-05-20 sal de peptìdeo de bpc com atividade organo-protetora, composição farmacêutica ou diagnóstica, usos e processos de preparação.

Country Status (28)

Country Link
US (1) US6288028B1 (pt)
EP (1) EP0983300B1 (pt)
JP (1) JP3492381B2 (pt)
KR (1) KR100488038B1 (pt)
CN (1) CN1166683C (pt)
AR (1) AR011478A1 (pt)
AT (1) ATE277948T1 (pt)
AU (1) AU731317B2 (pt)
BG (1) BG64023B1 (pt)
BR (1) BR9809457B1 (pt)
CA (1) CA2290739C (pt)
CZ (1) CZ299423B6 (pt)
DE (1) DE69826653T2 (pt)
DK (1) DK0983300T3 (pt)
EA (1) EA002058B1 (pt)
ES (1) ES2229507T3 (pt)
HU (1) HU227800B1 (pt)
ID (1) ID23184A (pt)
IL (2) IL132884A0 (pt)
NO (1) NO321126B1 (pt)
NZ (1) NZ501323A (pt)
PL (1) PL193790B1 (pt)
PT (1) PT983300E (pt)
RS (1) RS49733B (pt)
SK (1) SK159599A3 (pt)
TR (1) TR199902866T2 (pt)
UA (1) UA61955C2 (pt)
WO (1) WO1998052973A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4912875B2 (ja) * 2004-02-27 2012-04-11 不二製油株式会社 癌転移抑制組成物
US8022216B2 (en) * 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
SI24318A (sl) 2013-03-13 2014-09-30 Diagen D.O.O. Nove stabilne soli pentadekapeptida, postopek za njihovo pripravo, njihova uporaba za izdelavo farmacevtskih pripravkov in njihova uporaba v terapiji
US10350293B2 (en) 2016-08-23 2019-07-16 Pharmacotherapia d.o.o. Compositions and methods for treating symptoms associated with multiple sclerosis
HUE066356T2 (hu) 2017-08-24 2024-07-28 Novo Nordisk As GLP-1 készítmények és alkalmazásaik
PE20221575A1 (es) 2020-02-18 2022-10-06 Novo Nordisk As Formulaciones farmaceuticas
US11065298B1 (en) * 2020-04-24 2021-07-20 Chanda Zaveri Compositions and methods for treating or preventing viral infections
US12605427B2 (en) * 2023-05-15 2026-04-21 Red Mountain Med Spa, LLC Sublingual semaglutide-BPC 157 combination for weight loss

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2104704C1 (ru) * 1990-09-11 1998-02-20 Сикирич Предраг Фармакологически активная субстанция защитного соединения организма 3со, способ ее получения и терапевтическое применение
ATE152734T1 (de) * 1992-05-30 1997-05-15 Sikiric Predrag Bpc-peptide, deren herstellung und verwendung
RU2116311C1 (ru) 1992-11-16 1998-07-27 Сикирич Предраг Пептиды, обладающие органозащитной активностью, фармакологически активная композиция

Also Published As

Publication number Publication date
AU731317B2 (en) 2001-03-29
BR9809457B1 (pt) 2010-11-30
PL336897A1 (en) 2000-07-17
JP3492381B2 (ja) 2004-02-03
ID23184A (id) 2000-03-23
US6288028B1 (en) 2001-09-11
WO1998052973A1 (en) 1998-11-26
RS49733B (sr) 2008-04-04
EP0983300B1 (en) 2004-09-29
PL193790B1 (pl) 2007-03-30
JP2000515558A (ja) 2000-11-21
YU60199A (sh) 2002-09-19
AR011478A1 (es) 2000-08-16
CN1166683C (zh) 2004-09-15
DK0983300T3 (da) 2005-01-31
HUP0002329A3 (en) 2001-03-28
CZ299423B6 (cs) 2008-07-23
NZ501323A (en) 2001-04-27
BG103905A (en) 2000-07-31
TR199902866T2 (xx) 2000-02-21
NO321126B1 (no) 2006-03-20
IL132884A0 (en) 2001-03-19
SK159599A3 (en) 2000-11-07
CZ9904142A3 (cs) 2002-03-13
PT983300E (pt) 2005-02-28
HU227800B1 (en) 2012-03-28
ES2229507T3 (es) 2005-04-16
CA2290739A1 (en) 1998-11-26
CN1257510A (zh) 2000-06-21
EP0983300A1 (en) 2000-03-08
CA2290739C (en) 2007-06-26
EA199901061A1 (ru) 2000-06-26
UA61955C2 (en) 2003-12-15
BG64023B1 (bg) 2003-10-31
IL132884A (en) 2007-08-19
ATE277948T1 (de) 2004-10-15
DE69826653D1 (de) 2004-11-04
KR100488038B1 (ko) 2005-05-09
NO995692D0 (no) 1999-11-19
HUP0002329A1 (hu) 2000-12-28
DE69826653T2 (de) 2006-03-09
AU7914198A (en) 1998-12-11
KR20010012895A (ko) 2001-02-26
EA002058B1 (ru) 2001-12-24
NO995692L (no) 2000-01-24

Similar Documents

Publication Publication Date Title
BG103552A (bg) Терапевтични средства
BR9406363A (pt) Composiçao farmacêutica processo para a preparaçao da mesma uso da mesma e processo para o tratamento de doenças relacionadas com o ácido gástrico
BR0009042A (pt) Composto, uso do mesmo, processo para prepararum composto, composição farmacêutica, e, métodospara tratar uma doença em um animal em que aatividade de cisteìna protease contribui para apatologia e/ou sintomatologia da doença, e paratratar uma doença em um animal em que a atividadede catepsina s contribui para a patologia e/ousintomatologia da doença
BR0311313A (pt) Derivados de diaril uréia úteis para o tratamento de doenças dependentes de proteìna cinase
BRPI9915208A (pt) preparados farmacêutico e de comprimido para a aplicação oral compreendendo moxifloxacina e seu processo de preparação.
BR9006924A (pt) Formulacao para tratamento de sintomas e doencas,uso de formulacao para o tratamento de sintomas e doencas,metodo para o tratamento de sintomas e doencas,distribuicao de agentes medicinais e terapeuticos para o tratamento de sintomas e doencas e combinacao para administracao em mamiferos
BR9406720A (pt) Utilização de um adenovírus recombinante de origem animal adenovírus recombinante de origem animal e composição farmacêutica compreendendo um ou vários adenovírus
DE59905954D1 (de) Dialkylfumarate zur behandlung von autoimmunerkrankungen
ATE204467T1 (de) Orale darreichungsform
BR0015506A (pt) Conjugados de interferon gama, métodos para sua preparação, composições farmacêuticas que compreendem ás moléculas e seu uso no tratamento de doenças
BR0013010A (pt) Formulação de cloreto de sódio de moxifloxacina
CY1106152T1 (el) Νεα ανοσογονα αντι-hiv (ανατοξινες), μεθοδοι παρασκευης και εφαρμογη στην προληψη και στην αγωγη του aids
ATE198050T1 (de) Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
BR0012082A (pt) Formulação farmacêutica para administração compreendendo morfina e seu uso
BR0014946A (pt) Uso de dipiridamol ou mopidamol na fabricação de um medicamento para o tratamento e prevenção de distúrbios da microcirculação dependentes da fibrina
BRPI0407533A (pt) proteìnas de fusão e muteìnas do interferon alfa com propriedades melhoradas
KR940018087A (ko) 진통제 및 소염제로서의 6-클로로-5-플루오로-3-(2-테노일)-2-옥신돌-ⅰ-카복스아미드
PT101444A (pt) Associacao sinergizante com efeito antagonista dos receptores nk1 e nk2, uso de produtos com actividade antagonista dos receptores nk1 e nk2 na sua preparacao e composicao farmaceutica contendo a referida associacao
FI893681A0 (fi) N-2,3-butadienyltri- och tetra-aminoalkanderivat.
BR9913337A (pt) Derivados tan-1057
DE69939075D1 (de) Pharmazeutische Zusammenstellung zur Vorbeugung und Behandlung von mit Zellkrankheiten des Augenhintergrundes zusammenhängenden Krankheiten
PT983300E (pt) Sais peptidicos de bpc com actividade organo-protectora, processo para a sua preparacao e sua utilizacao em terapia
ATE3416T1 (de) Pharmakologisch aktive peptide und diese enthaltende arzneimittel.
BR9908716A (pt) Tratamento de disfunção sexual em certos grupos de pacientes
BRPI0418138A (pt) medicamento compreendendo ptx3, sozinho ou em combinação com tsg-6, para tratar doenças degenerativas de cartilagem e ósseas e tratar infertilidade feminina

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/11/2010, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)